Request Sample Form


Phone No.*:


Service Intersted In:

Download Complete Report

Your Name*:


Contact Number*:


Service Interested In* (required)

Your Requirment*:

Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access

Sandoz, a Novartis division and the global leader in biosimilars, announced a global resolution of all intellectual property related litigation with AbbVie concerning the proposed Sandoz biosimilar Hyrimoz® (adalimumab) for reference medicine Humira® (adalimumab).

October 12th, 2018|News|

EU green light for new Humira biosimilar

The European Commission has approved Mylan and Fujifilm Kyowa Kirin Biologics’ Humira biosimiar Hulio. The decision allows use of Hulio for all of Humira’s (adalimumab) approved indications, including rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of ankylosing spondylitis, psoriatic arthritis and psoriasis.

September 20th, 2018|News|